Clinics prefer calcium channel blockers

Published: 2010-05-19 06:58:00

Updated: 2010-05-19 06:58:00

Many clinics tend to prescribe calcium channel blocker (CCB) in newly diagnosed hypertensive patents, while general hospitals prefer angiotensin II receptor blockers (ARB) in the meta-analyses of 42,016 without cardiovascular disease conducted by the Health Insurance Review and Assessment Service...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK